About 30 results found for searched term "NC1" (0.012 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1787 | INCB18424 | JAK |
| Ruxolitinib | ||
| Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo. | ||
| M2039 | Baricitinib | JAK |
| INCB28050, LY3009104 | ||
| Baricitinib (INCB28050) is an oral JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively. | ||
| M2720 | IDO5L | IDO |
| INCB14943; INCB024360 analogue | ||
| IDO5L is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 67 nM. | ||
| M3030 | S-Ruxolitinib | JAK |
| S-Ruxolitinib; INCB18424 | ||
| S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. | ||
| M3068 | TIC10 | Akt |
| ONC-201; Dordaviprone | ||
| TIC10 (ONC-201) is a potent, orally active, and stable small molecule that transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier. | ||
| M3103 | UNC0631 | Histone Methyltransferase |
| UNC0631 is a selective histone lysine methyltransferase (HMTase) inhibitor for G9a and GLP with IC50 of 6 nM and 15 nM, respectively, with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity. | ||
| M3106 | UNC1215 | Epigenetic Reader Domain |
| UNC1215 is a potent and selective MBT (malignant brain tumor) antagonist, which binds L3MBTL3 with IC50 of 40 nM and Kd of 120 nM, 50-fold selective versus other members of the human MBT family. | ||
| M3107 | UNC1999 | EZH2 |
| UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. | ||
| M3194 | Nocodazole | Src-bcr-Abl |
| Oncodazole；R17934 | ||
| Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively. | ||
| M3207 | Tetracycline hydrochloride | Antibiotic |
| NCI-c55561; Tetracycline HCl | ||
| Tetracycline hydrochloride is a hydrochloride salt of tetracycline that is a broad-spectrum polyketide antibiotic. | ||
| M3291 | Hydroxyurea | DNA/RNA Synthesis |
| NSC-32065; NCI-C04831; Hydroxycarbamide | ||
| Hydroxyurea (NSC-32065) is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. | ||
| M3756 | Oncrasin-1 | DNA/RNA Synthesis |
| Oncrasin-1 is a small molecule RNA polymerase II inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations. | ||
| M3942 | Cephalotaxine | Anti-infection |
| (-)-Cephalotaxine; ZINC19795976 | ||
| Cephalotaxine is a benzazepine alkaloid isolated from Cephalotaxus harringtonia. | ||
| M3986 | Bruceantin | Antibiotic |
| (-)-Bruceantin; NCI165563; NSC165563 | ||
| Bruceantin was first isolated from Brucea antidysenterica, a tree used in Ethiopia for the treatment of cancer. | ||
| M4069 | (S)Ginsenoside-Rh1 | PPAR |
| Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1; Ginsenoside-Rh1 | ||
| Ginsenoside Rh1 (Prosapogenin A2) inhibited the expression of PPAR-γ, TNF-α, IL-6 and IL-1β. | ||
| M4101 | Notoginsenoside-R1 | Amyloid |
| Sanchinoside R1; Sanqi glucoside R1 | ||
| Notoginsenoside R1 (Sanchinoside R1) is a saponin isolated from P. notoginseng. Notoginsenoside R1 has antioxidant, anti-inflammatory, anti-angiogenic and anti-apoptotic activities. Notoginsenoside R1 provides cardiac protection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 may also provide neuroprotection. | ||
| M4875 | UNC2881 | TAM Receptor |
| UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively | ||
| M5315 | Baricitinib phosphate | JAK |
| INCB028050; LY3009104 | ||
| Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. | ||
| M5944 | Ruxolitinib phosphate | JAK |
| INCB018424 phosphate; INCB 018424 phosphate; INCB-018424 phosphate; Ruxolitinib | ||
| Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. | ||
| M6257 | ONC212 | Apoptosis |
| TR-31 | ||
| The ClpP activator ONC‐212 (TR‐31), a fluorinated-ONC201 analogue, is broadly efficacious across most solid tumors and hematological malignancies in the low nanomolar range and has robust anti-leukemic activity. | ||
| M6826 | INCA-6 | NFAT |
| INCA6; Triptycene-1,4-quinone | ||
| INCA-6 is a inhibitor of interaction between calcineurin and its substrate nuclear factor of activated T cells (NFAT). | ||
| M8017 | PTACH | Others |
| NCH-51 | ||
| HDAC inhibitor; more potent than the majority of HDAC inhibitors except for SAHA (gold standard). | ||
| M8280 | PSNCBAM-1 | Others |
| PSNCBAM-1 is an allosteric, non-competitive antagonist of CB-1. | ||
| M8606 | NCX 4016 | Others |
| NCX 4016 (nitroaspirin) is nitroderivative of aspirin that combines cyclooxygenase inhibitor with an NO donor. | ||
| M8781 | NCT-501 | ALDH |
| NCT-501 is a potent and selective inhibitor of Aldehyde dehydrogenase ALDH1A1, a dehydrogenase that has been found to be elevated in certain cancers and in cancer stem cells. | ||
| M9032 | ZINC00881524 | ROCK |
| ZINC00881524 is a potent and selective ROCK inhibitor. | ||
| M8876 | Itacitinib | JAK |
| INCB039110 | ||
| Itacitinib (INCB039110) is a potent, selective JAK1 inhibitor with an IC50 value of 2 nM for human JAK1. It has oral bioactivity and potential anti-tumor activity. | ||
| M9355 | UNC2541 | Others |
| UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 510 nM). | ||
| M9496 | Balaglitazone | PPAR |
| DRF-2593; NN-2344; NNC-610645 | ||
| Balaglitazone is an agonist of peroxisome proliferator-activated receptor (PPAR) γ, with an EC50 of 1.351 μM for human PPARγ. | ||
| M10035 | Semaglutide | GLP Receptor |
| Rybelsus; Ozempic; NN9535; OG217SC; NNC 0113-0217 | ||
| Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217) is a long-acting human GLP-1 analog, it is also a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
